Clinical Trials Browser

OTHER × Afatinib × Gastrointestinal × Clear all

NCT06302621 2026-01-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06085755 2025-12-15

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Phase 2 Recruiting

Gastrointestinal

Gallbladder Neoplasms

NCT04839471 2024-07-08

BEAR

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01522768 2023-11-01

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2 Completed

42 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05865132 2023-05-18

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02501603 2023-01-27

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT02451553 2022-06-07

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT04880811 2021-07-13

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT01679405 2019-09-06

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Phase 1 Terminated

9 enrolled 12 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03940976 2019-06-11

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02353936 2019-02-11

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02975141 2018-08-13

AFFECT

Phase 1 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT01919879 2018-05-08

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02274012 2017-03-14

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Phase 2 Withdrawn

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis